BioEntrepreuneur Bootcamp
From science to venture
Are you a biomedical founding team ready to take your idea to the next level? Join our BioEntrepreneur Bootcamp 2026 – a biomedical start-up business training program in Munich designed to help you develop, validate, and accelerate your business concept.
Date: 3 February 2026 to 26 March 2026
Time: Seven weeks, Tuesday-Thursday, full day
Location: Hybrid (virtually & BioM, Am Klopferspitz 19a, 82152 Martinsried-Planegg)
Costs: free for pre-seed teams from Bavaria
Pricing
- Start-up teams from Bavaria 99 €
- Pre-seed / start-ups international 199 €
NO SHOW FEE: for all teams 99 €
Application Period: 3 - 26 November 2025
Over seven weeks (sessions running from Tuesday to Thursday), participants engage in:
- 9 on-site days in Munich
- 12 full-day online sessions
- Plus, off-site teamwork on validation, strategy, and pitching etc.
Who should apply?
Pre-seed biomedical teams with an innovative idea in:
- Drugs and therapies
- Biotechnology diagnostics, prediction, or prognosis platforms
- Drug discovery & development technologies platforms
What you gain:
- Validate your concept with industry experts and potential partners
- Strengthen your team and business roadmap
- Learn about funding, IP, regulations, and deal-making essentials
- Connect with mentors, investors, and pharma leaders
Why join?
- Learn from top experts and gain hands-on expertise in business strategy, IP, financing, regulation, and partnering
- Work with mentors throughout the program
- Pitch to an expert jury at the final Demo Day
- Expand your stakeholder network
- Make sure your business model meets real market needs
Because every great idea deserves a great launchpad!
08.04.2026
Würzburger Start-up EMFRET Analytics treibt EMA601-Entwicklung gemeinsam mit Boehringer Ingelheim voran
Das Würzburger Biotech-Unternehmen EMFRET Analytics rückt mit seinem Antikörperprogramm EMA601 einen entscheidenden Schritt näher an die mögliche klinische Anwendung heran: Das Unternehmen…
07.04.2026
Gilead übernimmt Münchener Biotech-Unternehmen und m4-Award Gewinner Tubulis für bis zu 5 Milliarden US-Dollar
Das amerikanische Biopharmaunternehmen Gilead Sciences mit Sitz in Kalifornien übernimmt das Münchner Biotechnologieunternehmen Tubulis und baut damit seine Onkologie-Pipeline gezielt aus. Im…
25.03.2026
BayOConnect 2026: Agenda Expanded with New Sessions, Speakers and Perspectives – Registration Now Open for Europe’s Leading Biotech Forum
BayOConnect 2026 on 30 June - 1 July 2026 in Munich highlights what truly drives growth in biotechnology: Europe as a competitive innovation hub, capital turning innovation into scale, and…